Therapeutics News and Research

RSS

Astrazeneca Acquires Spirogen For Up To $440M

...

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Cell Therapeutics, Inc. today announced that the National Institute for Health and Care Excellence, a non-departmental public body of the Department of Health in the United Kingdom, issued second draft guidance on PIXUVRI (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.

15 Oct 2013

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Scientists at the University of Massachusetts Medical School have shown that diffuse large B-cell lymphoma (DLBCL) may be susceptible to treatment by re-activating the normal aging program in tumor cells so they can no longer divide.

15 Oct 2013

Scientists decode key molecular gateway for toxin that causes botulism

U.S. and German scientists have decoded a key molecular gateway for the toxin that causes botulism, pointing the way to treatments that can keep the food-borne poison out of the bloodstream.

12 Oct 2013

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

...

11 Oct 2013

ImmunoGen signs new license agreement with Novartis

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.

11 Oct 2013

Super-enhancers could play important roles in disease diagnostics and therapeutics

Having recently discovered a set of powerful gene regulators that control cell identity in a few mouse and human cell types, Whitehead Institute scientists are now showing that these regulators-which they named "super-enhancers"-act across a vast array of human cell types and are enriched in mutated regions of the genome that are closely associated with a broad spectrum of diseases.

11 Oct 2013

AGA partners with PENTAX Medical to improve patient care via innovative medical technologies

The American Gastroenterological Association (AGA) Institute announced a new partnership with PENTAX Medical. PENTAX Medical will provide substantial funding over three years to stimulate innovation that will advance the science and practice of gastroenterology and improve patient outcomes.

11 Oct 2013

Osiris Therapeutics agrees to sell ceMSC business to Mesoblast

Osiris Therapeutics, Inc. announced today that it has entered into an agreement with a wholly-owned subsidiary of Mesoblast Limited for the sale of Osiris' culture-expanded mesenchymal stem cell business, including Prochymal, in a transaction worth up to $100 million in initial consideration and milestone payments.

11 Oct 2013

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, achieved the first research milestone in its antibody therapeutics alliance with MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX), announced in February 2013.

10 Oct 2013

Researchers made breakthrough development in inhibitory therapeutic for hypersensitive allergic reactions

New research published in the journal Nature Chemical Biology shows that a group of scientists, led by faculty at the University of Notre Dame, has made concrete progress toward the development of the first-ever inhibitory therapeutic for Type I hypersensitive allergic reactions.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Thwarting Greatwall May Trigger Mitotic Collapse And Suppress Tumor Development

...

9 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Cell division is an essential process for the development of an organism. This process, however, can cause tumour growth when it stops working properly. Tumour cells accumulate alterations in their genetic material, and this makes them divide in an uncontrolled fashion, thus encouraging growth of the tumour.

9 Oct 2013

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million).

9 Oct 2013

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it is advancing its Development Candidate for ALN-AS1, an RNAi therapeutic targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of hepatic porphyrias including acute intermittent porphyria (AIP).

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Therapeutics News and Research

Astrazeneca Acquires Spirogen For Up To $440M

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

NICE issues second draft guidance on PIXUVRI for treatment of aggressive B-cell NHL

Study provides novel link between cellular aging and diffuse large B-cell lymphoma

Scientists decode key molecular gateway for toxin that causes botulism

Novartis Inks Agreement For Immunogen's "TAP" ADC Technology

ImmunoGen signs new license agreement with Novartis

Super-enhancers could play important roles in disease diagnostics and therapeutics

AGA partners with PENTAX Medical to improve patient care via innovative medical technologies

Osiris Therapeutics agrees to sell ceMSC business to Mesoblast

Heptares' StaR platform offers breakthrough solution to challenge associated with antibodies therapeutics

Researchers made breakthrough development in inhibitory therapeutic for hypersensitive allergic reactions

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Thwarting Greatwall May Trigger Mitotic Collapse And Suppress Tumor Development

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

CNIO researcher identifies new molecular mechanism that regulates genome stability, cell proliferation

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News